Ressources

Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.

 

 

The recent publication of a national guideline and quality standards in Canada have provided clinicians with new, evidence-based recommendations on safe, appropriate opioid use.

Original research | 2022
About prescribers, Clinical guidance, Chronic pain
Rapport | 2022
à propos des pharmaciens, les guides de pratique clinique, l'hésitation des prescripteurs
Commentary | 2022
About prescribers, Policy/Regulatory, Safer supply, Clinical guidance, Hesitancy of prescribers
Guidelines | 2022
Clinical guidance, Safer supply, Policy/Regulatory, About prescribers

This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal.

Original research | 2022
Stimulants, Withdrawal, Clinical guidance

We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.

Original research | 2022
Substitution/OAT, Clinical guidance

The therapeutic benefits of cannabinoids remain unclear, especially when weighted against their adverse effects.

Lit review | 2022
Withdrawal, Clinical guidance

This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms.

Lit review | 2022
Withdrawal, Stimulants, Clinical guidance
Guidelines | 2022
About prescribers, Substitution/OAT, Hospitals, Clinical guidance
Guide or handbook | 2022
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers

To understand what prescribing characteristics are associated with opioid overdose following buprenorphine taper.

Original research | 2022
Substitution/OAT, Overdose, Transitions in care/treatment, About PWUD, Clinical guidance
Handout | 2022
Clinical guidance, About pharmacists, About prescribers, Substitution/OAT, Transitions in care/treatment
Commentary | 2022
Withdrawal, About prescribers, Parents/caregivers, Clinical guidance
Guidelines | 2022
Withdrawal, Clinical guidance, Harm reduction, About prescribers
Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Illegal drugs, Substitution/OAT, Carries/take-home doses
Guidelines | 2021
Clinical guidance, Policy/Regulatory, About prescribers, Substitution/OAT, Carries/take-home doses, Illegal drugs
Guidelines | 2022
Clinical guidance, Policy/Regulatory, About prescribers, Harm reduction, Safer supply, Carries/take-home doses, Substitution/OAT
Guidelines | 2022
Clinical guidance, Carries/take-home doses, Policy/Regulatory

Affiner votre recherche

Mots clés
Format
Région